Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016 | 0.93 | — | — | |
| Ammonia Solution, Strong SCHEMBL23779796 | 0.86 | — | — | |
| Water SCHEMBL31291049 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL11590787 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL9280921 | 0.76 | — | — | |
| SCHEMBL28031875 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL9243249 | 0.68 | — | — | |
| Formic Acid SCHEMBL29763139 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL9243281 | 0.68 | — | — | |
| SCHEMBL9706972 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | claimed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | claimed |
| CN-120058798-A | Bicyclic TEAD inhibitors | 武汉人福创新药物研发中心有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| WO-2024217481-A1 | EGFR DEGRADING AGENT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024022244-A1 | HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY | 首药控股(北京)股份有限公司 | 2024-02-01 | — | — | WO | disclosed |
| CN-116891502-A | EGFR degrading agent | 上海齐鲁制药研究中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116888108-A | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-113302196-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-112771032-B | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors | 江苏先声药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022194269-A1 | NOVEL EGFR DEGRADATION AGENT | 上海齐鲁制药研究中心有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| CN-114644654-A | Oxidized aryl phosphorus derivative, acid salt or crystal form thereof, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-109790168-A | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | 吉利德科学公司 | 2019-05-21 | — | — | CN | disclosed |